Immunotherapy: Engineering a sTrategy for multiple myeloma

Nature Reviews Cancer

Volumn 15, Issue 9, 2015, Pages 514-

  Razzak, Mina ^a  

^a Nature Reviews Disease Primers   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; MELPHALAN; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER SURVIVAL; CELL ENGINEERING; CYTOKINE RELEASE SYNDROME; FOLLOW UP; GENE EXPRESSION; GENE TRANSFER; HUMAN; LYMPHOCYTE TRANSFER; MULTIPLE MYELOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; FEMALE; IMMUNOLOGY; MALE; PHYSIOLOGY;

ANTIGENS, NEOPLASM; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84940448322     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc4006     Document Type: Note

References (1)

1. Rapoport A. P., et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914-921 (2015